This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Amicus Therapeutics Announces Posters And Presentations At Lysosomal Disease Network WORLD Symposium

CRANBURY, N.J., Feb. 7, 2013 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced that 2 oral presentations and 5 posters related to its investigational pharmacological chaperones will be included at the 9 th Annual Lysosomal Disease Network WORLD Symposium ( LDN WORLD), to be held February 13-15, 2013 in Orlando, FL. The Company will host a conference call and live audio/visual webcast on Friday, February 15, 2013 at 11:30am ET to highlight the data presented at LDN WORLD.

Posters: Wednesday, February 13, 2013, 4:30-6:30pm ET and Thursday, February 14, 2013, 4:30-6:00pm ET

A Phase 2a Study to Investigate the Effect of a Single Dose of Migalastat HCl, a Pharmacological Chaperone, on Agalsidase Activity in Subjects with Fabry Disease – D. Warnock, D. Bichet, M. Holida, O. Goker-Alpan, K. Nicholls, M. Thomas, F. Eyskens, S. Shankar, G. Linthorst, M. Dasouki, F. K. Johnson, P. Boudes

A Phase 2a Study to Investigate Drug-Drug Interactions between Escalating Doses of AT2220 (Duvoglustat Hydrochloride) and Acid Alfa-Glucosidase in Subjects with Pompe Disease – P. Kishnani, M. Tarnopolsky, K. Sivakumar, M. Roberts, B. Byrne, O. Goker-Alpan, K. Guter, M. Pervaiz, M. Dasouki, T. Mozaffar, E. Finanger, F. Johnson, P. Boudes

Exploring the Use of a Co-Formulated Pharmacological Chaperone AT2220 with Recombinant Human Acid Alfa-Glucosidase for Pompe Disease – R. Khanna, S. Xu, Y. Lun, R. Soska, J. Feng, M. Frascella, A. Garcia, J. Flanagan, D. J. Lockhart, K. Valenzano

High Incidence of GLA Variants In A Non-Selected Heart Disease Patient Population Suggests That The Fabry Trait Is A Common Cardiovascular Genetic Risk Factor - R. Schiffman, S. Forni, C. Swift, X. Wu, D. J. Lockhart, M. Chee, T. Kitaoka, E. Chudin, S. Pond, N.H. McNeill, K. Sims, E.R. Benjamin, L. Sweetman

The Origins of Glucosylsphingosine in Gaucher Disease – J. Flanagan, B. Ranes, N. Brignol, R. Hamler, S.W. Clark

Oral Platform Presentations:

A Phase 2a Study to Investigate Drug-Drug Interactions between Escalating Doses of AT2220 (Duvoglustat Hydrochloride) and Acid Alfa-Glucosidase in Subjects with Pompe Disease – P. Kishnani, M. Tarnopolsky, K. Sivakumar, M. Roberts, B. Byrne, O. Goker-Alpan, K. Guter, M. Pervaiz, M. Dasouki, T. Mozaffar, E. Finanger, F. Johnson, P. Boudes

  • Friday, February 15, 2013, 9:15-9:30am ET (Mark Tarnopolsky, McMaster University)

Phase 3 Study of Migalastat HCl for Fabry Disease: Stage 1 Results. – K. Nicholls, D.P. Germain, C. Feliciani, S. Shankar, F. Ezgu, S.G. Janmohamed, S.M. Laing, R. Schroyer, A.C. Bragat, S. Sitaraman, P. Boudes

  • Friday, February 15, 2013, 10:30-10:45am ET (Fatih Ezgu, Gazi University)

Conference Call and Webcast:

John F. Crowley, Chairman and Chief Executive Officer, and members of the Amicus executive team will host a conference call and live audio/visual webcast on Friday, February 15, 2013 at 11:30am ET to discuss the data presented at LDN WORLD.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,928.20 -142.20 -0.79%
S&P 500 2,089.46 -25.03 -1.18%
NASDAQ 4,939.3270 -77.6020 -1.55%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs